These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 23896410)

  • 1. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
    Dos Santos C; McDonald T; Ho YW; Liu H; Lin A; Forman SJ; Kuo YH; Bhatia R
    Blood; 2013 Sep; 122(11):1900-13. PubMed ID: 23896410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
    Congleton J; MacDonald R; Yen A
    Leukemia; 2012 Jun; 26(6):1180-8. PubMed ID: 22182854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia.
    Lin WH; Wu SY; Yeh TK; Chen CT; Song JS; Shiao HY; Kuo CC; Hsu T; Lu CT; Wang PC; Wu TS; Peng YH; Lin HY; Chen CP; Weng YL; Kung FC; Wu MH; Su YC; Huang KW; Chou LH; Hsueh CC; Yen KJ; Kuo PC; Huang CL; Chen LT; Shih C; Tsai HJ; Jiaang WT
    J Med Chem; 2019 Dec; 62(24):11135-11150. PubMed ID: 31721578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.
    Rossi F; Yozgat Y; de Stanchina E; Veach D; Clarkson B; Manova K; Giancotti FG; Antonescu CR; Besmer P
    Mol Cancer Res; 2010 Sep; 8(9):1271-83. PubMed ID: 20736294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.
    Tokuhisa Y; Lidsky ME; Toshimitsu H; Turley RS; Beasley GM; Ueno T; Sharma K; Augustine CK; Tyler DS
    Ann Surg Oncol; 2014 Mar; 21(3):1024-30. PubMed ID: 24281418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
    Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
    Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
    Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O
    PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation.
    Mpakou VE; Kontsioti F; Papageorgiou S; Spathis A; Kottaridi C; Girkas K; Karakitsos P; Dimitriadis G; Dervenoulas I; Pappa V
    Leuk Res; 2013 Feb; 37(2):175-82. PubMed ID: 23149070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
    Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
    Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.
    Heo SK; Noh EK; Kim JY; Jeong YK; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
    Sci Rep; 2017 Nov; 7(1):15278. PubMed ID: 29127384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.
    Guerrouahen BS; Futami M; Vaklavas C; Kanerva J; Whichard ZL; Nwawka K; Blanchard EG; Lee FY; Robinson LJ; Arceci R; Kornblau SM; Wieder E; Cayre YE; Corey SJ
    Clin Cancer Res; 2010 Feb; 16(4):1149-58. PubMed ID: 20145167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo.
    Weir MC; Shu ST; Patel RK; Hellwig S; Chen L; Tan L; Gray NS; Smithgall TE
    ACS Chem Biol; 2018 Jun; 13(6):1551-1559. PubMed ID: 29763550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
    Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
    Faderl S; Pal A; Bornmann W; Albitar M; Maxwell D; Van Q; Peng Z; Harris D; Liu Z; Hazan-Halevy I; Kantarjian HM; Estrov Z
    Cancer Res; 2009 May; 69(9):3910-7. PubMed ID: 19383925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo.
    Saito Y; Yuki H; Kuratani M; Hashizume Y; Takagi S; Honma T; Tanaka A; Shirouzu M; Mikuni J; Handa N; Ogahara I; Sone A; Najima Y; Tomabechi Y; Wakiyama M; Uchida N; Tomizawa-Murasawa M; Kaneko A; Tanaka S; Suzuki N; Kajita H; Aoki Y; Ohara O; Shultz LD; Fukami T; Goto T; Taniguchi S; Yokoyama S; Ishikawa F
    Sci Transl Med; 2013 Apr; 5(181):181ra52. PubMed ID: 23596204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
    Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
    PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
    Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
    Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.